Saturday, November 13, 2021 12:25:43 PM
If everything is hunky dory which I expect it is, then I agree that Advent may well be the best alternative available to us at that time and with that funding. It could be a brilliant way to offer herself and her colleagues backside protection if things go well, meanwhile providing current shareholders much value.
If it is not, then there is a different lens by which we should look at these decisions because if we pass SNO bye without proper disclosure of material information to retail investors there begins to be questions asked which do not lead to protection of current shareholder value (and I mean current as before warrant extensions). If there are problems which are leading to delays, then we have a right to know just as much as any single one of those warrant holders and I have two paid advertisements that say so, unless some other more timely avenue is available to them. Journals do not prevent presentation at Congress from my experience, but the reverse is not necessarily true, and besides why would you especially after telling me that you would through paid advertisements. I am not making a threat, I am making an observation and there is a big difference.
I don’t want to slip back into negativity as I wish to let those feelings go and listen to my yoga instructor when he says that you find peace by accepting and trusting in the unknown.
There is a third pathway with many doorways to choose. I will continue to provide options in my free time at no charge to anyone who cares to read.
If it is not, then there is a different lens by which we should look at these decisions because if we pass SNO bye without proper disclosure of material information to retail investors there begins to be questions asked which do not lead to protection of current shareholder value (and I mean current as before warrant extensions). If there are problems which are leading to delays, then we have a right to know just as much as any single one of those warrant holders and I have two paid advertisements that say so, unless some other more timely avenue is available to them. Journals do not prevent presentation at Congress from my experience, but the reverse is not necessarily true, and besides why would you especially after telling me that you would through paid advertisements. I am not making a threat, I am making an observation and there is a big difference.
I don’t want to slip back into negativity as I wish to let those feelings go and listen to my yoga instructor when he says that you find peace by accepting and trusting in the unknown.
There is a third pathway with many doorways to choose. I will continue to provide options in my free time at no charge to anyone who cares to read.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
